RxDoctor Payments Data

Katherine Scrivner, DO

Internal Medicine · Hazelwood, MONPI 1972954741

Payments from drug & device makers

$1,060in general payments, 2019–2025

Across 55 payments — averaging $19.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$158
  • AstraZeneca$136
  • Ascendis Pharma Endocrinology Inc$85
  • Sanofi-aventis U.S. LLC$73
  • Lilly USA, LLC$61
  • Dexcom, Inc.$58
  • plus $487 from 18 others

What the payments were for

  • Food & beverage$1,060100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,060 in reported general payments places this provider in the 70th percentile of 2,097 internal medicine providers in Missouri.

See all internal medicine providers in Missouri

Medicare billing

Part B allowed, 2024
$43,388
Medicare patients
112
Services billed
1,272

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban122$94,654
OzempicSemaglutide50$53,014
JardianceEmpagliflozin37$49,040
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog32$45,284
TrulicityDulaglutide38$36,016
Trelegy ElliptaFluticasone/Umeclidin/Vilanter44$33,771
Spiriva RespimatTiotropium Bromide39$29,922
ProliaDenosumab14$23,977
XareltoRivaroxaban15$21,107
EntrestoSacubitril/Valsartan25$19,709
LinzessLinaclotide12$19,202
ArexvyRsvpref3 Antigen/As01e/Pf69$19,038
JanuviaSitagliptin Phosphate11$16,739
Semglee (Yfgn) PenInsulin Glargine-Yfgn22$14,990
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog18$13,588

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$158$53,01450 claims
Lilly USA, LLCTrulicity$61$36,01638 claims
AmgenProlia$15$23,97714 claims
MerckJanuvia$41$16,73911 claims
AstraZenecaFarxiga$136$7,29211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,097 internal medicine providers in Missouri.

Other internal medicine in Hazelwood

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →